These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 17633905)

  • 1. [High sensitivity of C-reactive protein in primary prevention].
    Corrado E; Novo S
    G Ital Cardiol (Rome); 2007 Jun; 8(6):327-34. PubMed ID: 17633905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
    Mora S; Ridker PM
    Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy.
    Koenig W
    Int J Cardiol; 2013 Oct; 168(6):5126-34. PubMed ID: 23978367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of C-reactive protein in primary and secondary prevention.
    Corrado E; Novo S
    J Investig Med; 2007 Dec; 55(8):430-8. PubMed ID: 18163969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: from concept to clinical practice to clinical benefit.
    Ridker PM
    Am Heart J; 2004 Jul; 148(1 Suppl):S19-26. PubMed ID: 15211329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical appraisal of inflammatory markers in cardiovascular risk stratification.
    Krintus M; Kozinski M; Kubica J; Sypniewska G
    Crit Rev Clin Lab Sci; 2014 Oct; 51(5):263-79. PubMed ID: 24918900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).
    Ridker PM; MacFadyen JG; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Circ Cardiovasc Qual Outcomes; 2009 Nov; 2(6):616-23. PubMed ID: 20031900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members.
    Di Napoli M; Schwaninger M; Cappelli R; Ceccarelli E; Di Gianfilippo G; Donati C; Emsley HC; Forconi S; Hopkins SJ; Masotti L; Muir KW; Paciucci A; Papa F; Roncacci S; Sander D; Sander K; Smith CJ; Stefanini A; Weber D
    Stroke; 2005 Jun; 36(6):1316-29. PubMed ID: 15879341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inflammation, C-reactive protein, and atherothrombosis.
    Ridker PM; Silvertown JD
    J Periodontol; 2008 Aug; 79(8 Suppl):1544-51. PubMed ID: 18673009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical use of high sensitivity C-reactive protein for the prediction of adverse cardiovascular events.
    Torres JL; Ridker PM
    Curr Opin Cardiol; 2003 Nov; 18(6):471-8. PubMed ID: 14597888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.
    Sever PS; Poulter NR; Chang CL; Thom SA; Hughes AD; Welsh P; Sattar N;
    J Am Coll Cardiol; 2013 Aug; 62(8):717-29. PubMed ID: 23948514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-sensitivity C-reactive protein and cardiovascular disease: a resolute belief or an elusive link?
    Yousuf O; Mohanty BD; Martin SS; Joshi PH; Blaha MJ; Nasir K; Blumenthal RS; Budoff MJ
    J Am Coll Cardiol; 2013 Jul; 62(5):397-408. PubMed ID: 23727085
    [TBL] [Abstract][Full Text] [Related]  

  • 14. C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.
    Tsimikas S; Willerson JT; Ridker PM
    J Am Coll Cardiol; 2006 Apr; 47(8 Suppl):C19-31. PubMed ID: 16631506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation and atherosclerosis: the value of the high-sensitivity C-reactive protein assay as a risk marker.
    Jialal I; Devaraj S
    Am J Clin Pathol; 2001 Dec; 116 Suppl():S108-15. PubMed ID: 11993695
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-sensitivity C-reactive protein as cardiovascular risk marker in patients with diabetes mellitus.
    Pfützner A; Forst T
    Diabetes Technol Ther; 2006 Feb; 8(1):28-36. PubMed ID: 16472048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial.
    Dosh K; Berger PB; Marso S; van Lente F; Brennan DM; Charnigo R; Topol EJ; Steinhubl S
    Circ Cardiovasc Interv; 2009 Dec; 2(6):503-12. PubMed ID: 20031767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of C-reactive protein in cardiovascular disease.
    Backes JM; Howard PA; Moriarty PM
    Ann Pharmacother; 2004 Jan; 38(1):110-8. PubMed ID: 14742804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interrelationships between inflammation, C-reactive protein, and insulin resistance.
    Ndumele CE; Pradhan AD; Ridker PM
    J Cardiometab Syndr; 2006; 1(3):190-6. PubMed ID: 17679826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.